title: Treating DVT: answers to 7 key questions.
authors.affiliation: The James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH 45267, USA. metzgean@ucmail.uc.edu
authors.forename: Anne H
authors.initials: AH
authors.lastname: Metzger
authors.forename: Patricia R
authors.initials: PR
authors.lastname: Wigle
authors.forename: Bradley E
authors.initials: BE
authors.lastname: Hein
authors.forename: Kim
authors.initials: K
authors.lastname: Thrasher
authors.forename: Karissa Y
authors.initials: KY
authors.lastname: Kim
authors.forename: Joseph
authors.initials: J
authors.lastname: Kiesler
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use*; D000077425:Fondaparinux; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006801:Humans; D011134:Polysaccharides / Q000627:therapeutic use; D016896:Treatment Outcome; D020246:Venous Thrombosis / Q000188:drug therapy*; D014859:Warfarin / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D011134:Polysaccharides; D014859:Warfarin; D000077425:Fondaparinux